Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

World-famous video performer Uta is about to make her in-person concert debut on the island of Elegia. The Strawhat crew joins millions of others to see Uta in real life, only to have Luffy tell ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Jinhuei Enya Dai is a practitioner and researcher who believes that pedagogy is theory in practice, and has dedicated herself to innovative pedagogy, an ecological perspective, content-based ...

The Quarterly Results page of Dai Ichi Karkaria Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.